The in-house R&D activity gives Faes the possibility to innovate its own products and develop new molecules to deliver them to third parties worldwide. For example, our flagship molecule bilastine.
Once approved in Europe, the bilastine outlicensing activity boomed in 2011. Granting commercialization rights to other pharmaceutical companies, many partners joined the bilastine project (Menarini, Taiho, Pfizer, Takeda, GSK, etc), thus covering the needs of allergic patients around the world, and being marketed in more than 80 countries up to dated.
Faes is actively working in R&D+i to be able to offer our products to potential marketers.
Within the out-licensing activity, Faes is looking for:
- Granting commercialization rights of our own products on an international level.
- Improving and innovating own products (formulation, dose, efficacy, indication, etc.) to make them available to third parties world wide.
- Co-developing projects with third parties to obtain final products suitable for other territories.